Iyar Mazar

457 total citations
20 papers, 313 citations indexed

About

Iyar Mazar is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Iyar Mazar has authored 20 papers receiving a total of 313 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 4 papers in Pediatrics, Perinatology and Child Health and 4 papers in Oncology. Recurrent topics in Iyar Mazar's work include Economic and Financial Impacts of Cancer (5 papers), Childhood Cancer Survivors' Quality of Life (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Iyar Mazar is often cited by papers focused on Economic and Financial Impacts of Cancer (5 papers), Childhood Cancer Survivors' Quality of Life (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Iyar Mazar collaborates with scholars based in United States, United Kingdom and France. Iyar Mazar's co-authors include Alan L. Shields, Meaghan Krohe, Daniel Eek, Farrah Pompilus, Yanni Hao, Denise Globe, Catherine Foley, Jonathan Stokes, Andrew Yaworsky and Roger E. Lamoureux and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Therapeutics.

In The Last Decade

Iyar Mazar

19 papers receiving 306 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iyar Mazar United States 9 93 66 49 44 37 20 313
Meaghan Krohe United States 9 109 1.2× 47 0.7× 59 1.2× 51 1.2× 40 1.1× 19 336
Anthony Louder United States 11 56 0.6× 69 1.0× 32 0.7× 72 1.6× 33 0.9× 17 353
Przemysław Holko Poland 12 63 0.7× 52 0.8× 41 0.8× 48 1.1× 18 0.5× 33 358
Farrah Pompilus United States 9 65 0.7× 94 1.4× 45 0.9× 37 0.8× 49 1.3× 23 357
Karen E. Wickersham United States 9 76 0.8× 39 0.6× 29 0.6× 37 0.8× 39 1.1× 21 265
Scott A. Soefje United States 8 139 1.5× 71 1.1× 35 0.7× 23 0.5× 39 1.1× 29 369
Amy M. Pick United States 8 49 0.5× 47 0.7× 33 0.7× 22 0.5× 41 1.1× 24 294
Filiz Çay Şenler Türkiye 10 202 2.2× 48 0.7× 110 2.2× 15 0.3× 35 0.9× 40 417
Anna Rachelle Mislang Australia 11 130 1.4× 21 0.3× 62 1.3× 31 0.7× 17 0.5× 26 298
Julie Couture Canada 12 70 0.8× 98 1.5× 23 0.5× 49 1.1× 17 0.5× 20 378

Countries citing papers authored by Iyar Mazar

Since Specialization
Citations

This map shows the geographic impact of Iyar Mazar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iyar Mazar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iyar Mazar more than expected).

Fields of papers citing papers by Iyar Mazar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iyar Mazar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iyar Mazar. The network helps show where Iyar Mazar may publish in the future.

Co-authorship network of co-authors of Iyar Mazar

This figure shows the co-authorship network connecting the top 25 collaborators of Iyar Mazar. A scholar is included among the top collaborators of Iyar Mazar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iyar Mazar. Iyar Mazar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gwaltney, Chad, Jonathan Stokes, Iyar Mazar, et al.. (2022). Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease. Journal of Patient-Reported Outcomes. 6(1). 129–129. 4 indexed citations
2.
Taylor, Fiona, Cem Akin, Roger E. Lamoureux, et al.. (2021). Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©. Orphanet Journal of Rare Diseases. 16(1). 414–414. 9 indexed citations
3.
Gwaltney, Chad, et al.. (2021). Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults. Orphanet Journal of Rare Diseases. 16(1). 264–264. 6 indexed citations
4.
Mazar, Iyar & Sara M. Moorman. (2021). “I Want That Life a Lot…How on Earth Do I Get That?” Examining Challenges for Men With Barth Syndrome in Their Transitions to Adulthood. SHILAP Revista de lepidopterología. 8. 652570159–652570159. 1 indexed citations
5.
Gwaltney, Chad, et al.. (2020). Development of a Patient-Reported Outcome Questionnaire to Evaluate Primary Mitochondrial Myopathy Symptoms: The Primary Mitochondrial Myopathy Symptom Assessment. Journal of Clinical Neuromuscular Disease. 22(2). 65–76. 1 indexed citations
6.
Mazar, Iyar, et al.. (2019). Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study. Orphanet Journal of Rare Diseases. 14(1). 243–243. 18 indexed citations
7.
8.
9.
Litcher‐Kelly, Leighann, et al.. (2018). PSY213 - WHAT MATTERS TO INDIVIDUALS WITH SICKLE CELL DISEASE? PATIENT INPUT ON THE RELEVANT AND IMPORTANT SYMPTOMS AND IMPACTS OF THE CONDITION. Value in Health. 21. S472–S473. 1 indexed citations
10.
Litcher‐Kelly, Leighann, et al.. (2018). Measurement of Sickle Cell Disease Symptoms from the Patient Perspective: Considerations for Clinical Trials. Blood. 132(Supplement 1). 3571–3571. 1 indexed citations
11.
Skup, Martha, et al.. (2017). Development of the Rheumatoid Arthritis Symptom Questionnaire (RASQ): a patient reported outcome scale for measuring symptoms of rheumatoid arthritis. Current Medical Research and Opinion. 33(9). 1643–1651. 8 indexed citations
12.
Krohe, Meaghan, et al.. (2016). Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Preference and Adherence. Volume 10. 1609–1621. 180 indexed citations
13.
Hao, Yanni, Meaghan Krohe, Andrew Yaworsky, et al.. (2016). Clinical Trial Patient-reported Outcomes Data: Going Beyond the Label in Oncology. Clinical Therapeutics. 38(4). 811–820. 5 indexed citations
14.
Krohe, Meaghan, Yanni Hao, Roger E. Lamoureux, et al.. (2016). Patient-Reported Outcomes in Metastatic Breast Cancer: A Review of Industry-Sponsored Clinical Trials. Breast Cancer Basic and Clinical Research. 10. BCBCR.S39385–BCBCR.S39385. 19 indexed citations
15.
Hao, Yanni, Meaghan Krohe, Iyar Mazar, et al.. (2016). Patient-reported outcomes in advanced breast cancer: inside the label and approval documents. 1(3). 197–205. 1 indexed citations
16.
Turner‐Bowker, Diane M., Yanni Hao, Catherine Foley, et al.. (2016). The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature. Current Medical Research and Opinion. 32(10). 1709–1717. 18 indexed citations
17.
Shields, Alan L., Yanni Hao, Meaghan Krohe, et al.. (2016). Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.. PubMed. 9(4). 188–97. 11 indexed citations
18.
Mazar, Iyar, et al.. (2015). Telephone Versus face-to-face Interviews for Patient-Reported Outcome Instrument Development. Value in Health. 18(7). A718–A718. 4 indexed citations
19.
Shields, Alan L., Cheryl D. Coon, Yanni Hao, et al.. (2015). Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods. Expert Review of Pharmacoeconomics & Outcomes Research. 15(6). 951–959. 14 indexed citations
20.
Mazar, Iyar, et al.. (2013). Understanding Foreclosure Risk: The Role of Nativity and Gender. Critical Sociology. 41(1). 115–132. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meaghan Krohe Breakdown of academic impact, for papers by Anthony Louder Breakdown of academic impact, for papers by Przemysław Holko Breakdown of academic impact, for papers by Farrah Pompilus Breakdown of academic impact, for papers by Karen E. Wickersham Breakdown of academic impact, for papers by Scott A. Soefje Breakdown of academic impact, for papers by Amy M. Pick Breakdown of academic impact, for papers by Filiz Çay Şenler Breakdown of academic impact, for papers by Anna Rachelle Mislang Breakdown of academic impact, for papers by Julie Couture
Rankless by CCL
2026